Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; the references it cites are not checked yet.

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study

Open access

Abstract

Injectable semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that was previously shown to be superior to liraglutide and dulaglutide in head-to-head comparisons in GLP-1 RA-naïve individuals. It is hypothesized that semaglutide will cause further reductions in glycated hemoglobin A1c (HbA1c) and weight in type 2 diabetes mellitus (T2DM) patients previously treated with liraglutide or dulaglutide. The REALISE-DM study provides the first real-world evidence of the effectiveness and tolerability of semaglutide in patients switching from another GLP-1 RA. This retrospective real-world effectiveness analysis included T2DM adults who were on a stable dose of liraglutide or dulaglutide prior to switching to semaglutide. The primary outcome was change in HbA1c. Secondary outcomes were the changes in weight and body mass index (BMI), the occurrence of gastrointestinal side effects (GSEs), and discontinuations. Linear mixed models were used to estimate changes in HbA1c, weight, and BMI, and logistic regression was employed to analyze GSEs and discontinuations. Six months after the 164 patients in this study had switched to semaglutide, their mean HbA1c had decreased by 0.65% (7.1 mmol/mol) (95% prediction interval [PI]: 0.48, 0.81% [5.2, 8.9 mmol/mol]) from a baseline of 7.9% (interquartile range [IQR]: 7.3, 8.8) (62.8 mmol/mol [IQR: 56.3, 72.7]), while their weight and BMI had reduced by 1.69 kg (95% PI: 1.01, 2.37) and 0.59 kg/m 2 (95% PI: 0.34, 0.84), respectively. Nineteen patients (11.6%) developed GSEs after switching. This study supports switching T2DM patients on liraglutide or dulaglutide to injectable semaglutide to achieve further reductions in HbA1c and weight. Although a small number of GSEs occurred, semaglutide was well tolerated by the majority of the patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-020-00984-x

Cites

Statistics

Figures

Fig. 1 Change in HbA1c over time after semaglutide OW initiation, stratified by baseline HbA1c level. BL baseline, HbA1c glycated hemoglobin A1c, OW once weekly
Fig. 1 Change in HbA1c over time after semaglutide OW initiation, stratified by baseline HbA1c level. BL baseline, HbA1c glycated hemoglobin A1c, OW once weeklyCC BY-NC · PubMed Central
Fig. 2 Change in weight over time after semaglutide OW initiation. OW once weekly
Fig. 2 Change in weight over time after semaglutide OW initiation. OW once weeklyCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 16 · Cited by 47

Metadata

Authors
Jain, A. B., Kanters, S., Khurana, R., Kissock, J., Severin, N., & Stafford, S. G.
Affiliations
  • University of British Columbia (CA)
  • Fraser Health (CA)
Corresponding author
Jain, Akshay B.
Venue
Diabetes Therapy
Published
2020-12-26
Volume
12
Issue
2
Pages
527-536
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3114726363
Cited by
47
References
16
Citations by year
2026: 3 · 2025: 8 · 2024: 12 · 2023: 8 · 2022: 9 · 2021: 6 · 2020: 1
FWCI
4.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novo Nordisk Canada
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, liraglutide, dulaglutide, type 2 diabetes, GLP-1 receptor agonists, drug switching, HbA1c, weight loss, body mass index, gastrointestinal adverse effects, treatment discontinuation, real-world effectiveness, weight loss maintenance, glycemic control, tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study. https://app.cochat.ai/papers/10.1007/s13300-020-00984-x
The paper
Jain, A. B., Kanters, S., Khurana, R., Kissock, J., Severin, N., & Stafford, S. G. (2021). Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00984-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.